Ajinomoto Co., Ltd.

Katsumi Maezono

Toshihiro Hatanaka

Koji Ohsumi

Hiroyuki Matsueda

Nobuo Kondo

Yoko Kageyama

Nozomu Ishida

Takashi Umemura

Akiko Onuki

Hideyuki Tanaka

Toshihiko Yoshimura

Naoyuki Fukuchi

Yayoi Kawato

Akiko Oonuki

Ryusuke Hirama

Osamu Ikehara

Kazunori Mawatari

Toshio Maki

Hiromitsu Arai

The present invention provides PPAR (peroxisome proliferator-activated receptor) activity regulators, which can be widely used for improving insulin resistance and preventing/treating various diseases such as diabetes, metabolic syndromes, hyperlipemia, high-blood pressure, vascular disorders, inflammation, hepatitis, fatty liver, liver fibrosis, NASH (non-alcoholic steatohepatitis) and obesity.

PPAR activity regulators

The invention provides a prophylactic and therapeutic agent of diabetes mellitus, including a combination of an inhibitor of renal glucose reabsorption and a hypoglycemic agent. In accordance with the invention, hyperglycemia after meals, between meals and during fasting can be ameliorated. More specifically, in accordance with the invention, a therapeutic effect of diabetes mellitus as never been obtained by the hypoglycemic agents of the related art can be achieved.

Prophylactic and therapeutic agent of diabetes mellitus

The present invention provides an acylamide compound of the following formula (1), prodrugs thereof, or pharmaceutically acceptable salts thereof; and an adiponectin inducer or secretagogue, therapeutic agent of metabolic syndromes, therapeutic agent of hypoadiponectinemia, therapeutic agent of hyperlipemia, preventive/therapeutic agent of diabetes, improving agent of impaired glucose tolerance, improving agent of insulin resistance, enhancing agent of insulin sensitivity, therapeutic agent of hypertension, preventive/therapeutic agent of vascular disorders, an anti-inflammatory agent, therapeutic agent of hepatic inflammation, therapeutic agent of fatty liver, therapeutic agent of hepatic fibrosis, therapeutic agent of liver cirrhosis, preventive/therapeutic agent of non-alcoholic/nonviral steatohepatitis (NASH) or non-alcoholic/nonviral fatty liver disease (NAFLD), or therapeutic agent of obesity, each of which has the above compounds as an active ingredient. 

Acylamide compounds having secretagogue or inducer activity of adiponectin

The object of the present invention is to provide PPAR (peroxisome proliferator-activated receptor) activity regulators, which can be widely used for improving insulin resistance and preventing/treating various diseases such as diabetes, metabolic syndromes, hyperlipemia, high-blood pressure, vascular disorders, inflammation, hepatitis, fatty liver, liver fibrosis, NASH (non-alcoholic steatohepatitis) and obesity. The present invention provides PPAR activity regulators which comprise an acylamide compound having the specific structure, prodrugs thereof, or pharmaceutically acceptable salts thereof.

The present invention provides pyrazole-O-glycoside derivatives represented by the following formulae, used as a diabetic medicine. 

Pyrazole derivatives and diabetic medicine containing them

The present invention provides pyrazole-O-glycoside derivatives represented by the following formulae, used as a diabetic medicine 

The present invention provides pyrazole-O-glycoside derivatives represented by the following formulae, used as a diabetic medicine.

The present invention relates to pyrazole derivatives represented by the following formulas and analogues thereof, which can be used for a therapeutic agent for diabetes.

N-substituted pyrazole-O-glycoside derivatives and therapeutic agent for diabetes containing the same

A method of treating a patient in need of stimulation of hepatocyte mitosis which comprises administering to said patient an effective amount of alanine and/or glutamine.

Growing community of inventors

Kawasaki, Japan

Katsumi Maezono